William Chou, M.D. has served as our Chief Executive Officer and member of our Board of Directors since October 2022. Dr. Chou is an accomplished executive with nearly 20 years of healthcare experience across a range of development and commercialization roles. Dr. Chou previously served as CEO of Aruvant Sciences (Aruvant), a clinical-stage biopharmaceutical company focused on developing gene therapies for rare disease, from November 2019 to October 2022. Prior to joining Aruvant, from May 2008 to October 2019, Dr. Chou served in a variety of leadership roles at Novartis Pharma AG (Novartis), including Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy where he oversaw the global commercial launch of Kymriah®, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah® lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an MBA from the Yale School of Management, an MD from the University of Pittsburgh School of Medicine, and an AB in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

Kathleen Borthwick has served as Chief Financial Officer since March 2024. From November 2021 to March 2024, Ms. Borthwick served as Interim Chief Financial Officer and Vice President of Finance. From June 1997 to October 2021, Ms. Borthwick served in various leadership roles of increasing responsibility at Johnson & Johnson Services, Inc. During her tenure at Johnson & Johnson, she worked in Finance in support of Research & Development, Manufacturing, Business Development, Treasury and commercial operations for global Pharmaceutical and Medical Technology business segments. Ms. Borthwick earned her B.S. in Economics with concentrations in Accounting and Health Care Management at the Wharton School of University of Pennsylvania, and her M.B.A. from the Tuck School of Business at Dartmouth College.

Stuart Henderson has served as Chief Business Officer since August 2024. From February 2021 to August 2024, Mr. Henderson served as Senior Vice President, Corporate Development & Investor Relations and Vice President, Investor Relations & Strategic Finance. Prior to joining Passage Bio, Mr. Henderson held various senior leadership roles at TELA Bio, a medical technology company, across marketing, corporate development, and investor relations, from April 2013 to February 2021. While at TELA Bio, Mr. Henderson played a critical role in leading the company’s IPO and raising over $200 million in aggregate proceeds across equity, debt, and strategic financings. Earlier in his career, Mr. Henderson worked at Quaker Partners, a healthcare venture capital and growth equity firm, and at ZS Associates, where he focused on pharmaceutical sales and marketing strategy. Mr. Henderson earned his B.A. in Biological Sciences with a concentration in Neurobiology from Cornell University.

Maxine Gowen, Ph.D. has served as a member of our Board of Directors since February 2021, and as Chairperson of the Board of Directors since September 2021. Dr. Gowen currently serves on the boards of directors for Merus N.V. and Aclaris Therapeutics, Inc., each a public biotechnology company. Prior to that, Dr. Gowen served as Chief Executive Officer of Tamuro Bio from July 2019 to December 2021, and as the founding President and Chief Executive Officer of Trevena, Inc., from 2007 to October 2018, where she served as a member of Trevena’s board of directors from 2008 to 2021. Dr. Gowen previously held a variety of leadership roles at GlaxoSmithKline over a period of 15 years. Additionally, Dr. Gowen served on the board of Akebia Therapeutics, Inc from 2014 to 2021, the board of Idera Pharmaceuticals from 2016 to 2022, the board of directors and executive committee of BIO, an industry association, from 2008 to 2018, and the board of directors and executive committee of Life Sciences Pennsylvania, an industry association from 2016 to 2021. Dr. Gowen received a B.Sc. in biochemistry from the University of Bristol, U.K., a Ph.D. in cell biology from the University of Sheffield, U.K., and an M.B.A. from the Wharton School of the University of Pennsylvania.

William Chou, M.D. has served as our Chief Executive Officer and member of our Board of Directors since October 2022. Dr. Chou is an accomplished executive with nearly 20 years of healthcare experience across a range of development and commercialization roles. Dr. Chou previously served as CEO of Aruvant Sciences (Aruvant), a clinical-stage biopharmaceutical company focused on developing gene therapies for rare disease, from November 2019 to October 2022. Prior to joining Aruvant, from May 2008 to October 2019, Dr. Chou served in a variety of leadership roles at Novartis Pharma AG (Novartis), including Vice President and Global Disease Lead for Novartis’ Cell and Gene Therapy where he oversaw the global commercial launch of Kymriah®, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah® lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr. Chou holds an MBA from the Yale School of Management, an MD from the University of Pittsburgh School of Medicine, and an AB in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.

Athena Countouriotis, M.D. has served as a member of our Board of Directors since February 2020. Dr. Countouriotis has served as Chief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics, a private oncology therapeutics company, since October 2022. Dr. Countouriotis currently serves on the board of directors of BioMarin Pharmaceutical Inc., a public pharmaceutical company, Iovance Biotherapeutics, Inc., a public oncology therapeutics company, Recludix Therapeutics, Inc., a private oncology therapeutics company, Leal Therapeutics, Inc., a private central nervous system diseases company, and Capstan Therapeutics, Inc, a private cell therapy company. Prior to that, Dr. Countouriotis served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. from September 2018 to August 2022, and as Chief Medical Officer of Turning Point Therapeutics from May 2018 to September 2018. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018, and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit’s acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. In addition, Dr. Countouriotis previously served on the board of directors of Cardiff Oncology, a public oncology therapeutics company. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. Dr. Countouriotis received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.

Derrell D. Porter, M.D. has served as member of our Board of Directors since May 2021. Dr. Porter has served as Chief Executive Officer and as member of the board of directors of cTRL Therapeutics, Inc., since November 2023. Dr. Porter has served on the board of directors of Acumen Pharma, a public company, since January 2023, and currently serves on the boards of directors of several private companies. Previously, Dr. Porter served as Founder and Chief Executive Officer at Cellevolve Bio, Inc., a privately held biotechnology company from March 2020 to November 2023. Prior to that, Dr. Porter served as SVP and Head of Commercial at Atara Biotherapeutics, Inc. from May 2017 to October 2019. Prior to joining Atara, Dr. Porter served as a Vice President with Gilead Sciences from April 2013 to May 2017, where he was responsible for corporate strategy, commercial planning, and global launch preparation for all of Gilead’s therapeutic areas. Previously, Dr. Porter was at AbbVie and Amgen, where he served in multiple US, EU and global roles of increasing responsibility in strategy, corporate development, business unit management, and sales & marketing. Dr. Porter began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. Dr. Porter holds an M.D. from the University of Pennsylvania, where he was a Twenty First Century Scholar, an M.B.A. from The Wharton School and a Bachelor’s degree in neuroscience from the University of California Los Angeles.

Dolan Sondhi, Ph.D. has served as a member of our board of directors since July 2023. Dr. Sondhi is a Professor of Research in the Department of Genetic Medicine at Weill Cornell Medicine, having held numerous academic appointments there since 1999. Dr. Sondhi is also the Associate Director of the Belfer Gene Therapy Core Facility, a clinical vector manufacturer, as well as the Manager for all Neurological and Translational Gene Therapy Projects within the Department of Genetic Medicine. Prior to Weill Cornell, she completed her post-doctoral fellowship at Rockefeller University. Dr. Sondhi holds a Ph.D. in Chemistry from Brown University and a Bachelor of Science in Chemistry (Honors) from St. Stephens College, Delhi University. Dr. Sondhi is also a member of the Scientific Advisory Board of Form Bio, a startup focused on the use of artificial intelligence in improving gene therapy manufacturing..

Sandip Kapadia has served as a member of our Board of Directors since January 2020. Mr. Kapadia has served as the Chief Financial Officer of Harmony Biosciences Holdings, Inc., a public biopharmaceutical company, since March 2021. Mr. Kapadia also serves on the board of directors of Molecular Partners AG and Alentis Therapeutics AG. Mr. Kapadia previously served as the Chief Financial Officer for Intercept Pharmaceuticals, Inc. from July 2016 to March 2021. Prior to that, Mr. Kapadia served in various leadership capacities within finance over 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the U.S. Mr. Kapadia previously served on the board of directors of VectivBio AG from October 2020 to July 2023. Mr. Kapadia received a B.S. in Accounting from Montclair State University and an M.B.A. from Rutgers University, and is also a U.S. Certified Public Accountant.

Thomas Kassberg has served as a member of our Board of Directors since September 2024. Mr. Kassberg currently serves as Chief Business Officer and Executive Vice President, of Ultragenyx Pharmaceutical Inc., a biotechnology company, positions he has held since January 2016 and November 2011, respectively. Prior to Ultragenyx, Mr. Kassberg worked as Vice President of Business Development at Corium International, Inc., a biotechnology company, from July 2010 to October 2011. Mr. Kassberg has also worked as an independent consultant in corporate development and business strategy and consulted with a number of companies from March 2009 to June 2010, including Corium International, Inc. and Rib-X Pharmaceuticals, Inc., a pharmaceutical company focused on the development of novel antibiotics. Before becoming a consultant, Mr. Kassberg worked at Proteolix, Inc., a biotechnology company subsequently acquired by Onyx Pharmaceuticals, from January 2008 to February 2009, where he served as Senior Vice President of Corporate Development. Mr. Kassberg earned his M.B.A. from Northwestern University’s Kellogg School of Management, and his B.A. in economics and management from Gustavus Adolphus College.